- Tonix Pharmaceuticals Holding Corp TNXP said in a regulatory filing that plans are underway to construct a commercial-scale manufacturing site to develop and manufacture vaccines, including its experimental COVID-19 shot, TNX-1800.
- The Montana facility intended to develop and manufacture Tonix’s vaccine candidates will be a “public/private sector collaboration between Ravalli County and Tonix Pharmaceuticals that will bring more high-tech bioscience jobs to the Bitterroot Valley,” the company said.
- Early this week, Tonix announced its plans to develop the fibromyalgia candidate, TNX-102 SL, as a potential treatment for Long COVID Syndrome.
- Price Action: TNXP shares are up 13.6% at $1.25 during the premarket session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
